Healthcare Fund Likes ‘Orphan Drugs’

June 25, 2009  

For its long book global healthcare firm Arcoda Capital Management is sticking to companies it believes will not be affected no matter what healthcare reform the U.S. Congress decides upon later this year—those which produce “orphan” drugs, or drugs developed specifically to treat a rare medical condition.

For its long book global healthcare firm Arcoda Capital Management is sticking to companies it believes will not be affected no matter what healthcare reform the U.S. Congress decides upon later this year—those which produce “orphan” drugs, or drugs developed specifically to treat a rare medical condition.

Michael Meyers, founder, ceo and cio, said the Arcoda Global Healthcare Fund likes companies with orphan drugs which are...

This article was originally published in Alternative Investment News.

Subscribe

Subscribers have unlimited access to all current and archive content. Start your subscription today - click on the button below.

Subscribe now

Free trial

Taking a free trial will give you access to the current issue for two weeks (excluding some surveys and articles). Start your trial today.

Free Trial



Latest Poll

Will John Paulson be back on the Rich List next year?

 - 31%
 - 69%

View previous results


Latest issue

VIEW ONLINE NOW